Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
67.04 USD | -0.06% | +0.36% | +7.73% |
May. 16 | Axonics Implant Approved in Australia to Treat Overactive Bladders | MT |
May. 16 | Axonics, Inc. Receives Regulatory Approval for Recharge-Free SNM System in Australia | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.73% | 3.42B | |
-4.78% | 11.52B | |
-4.86% | 8.3B | |
+42.16% | 5.73B | |
-20.87% | 4.69B | |
-19.39% | 2.54B | |
-13.36% | 2.03B | |
-16.39% | 1.86B | |
-31.24% | 1.59B | |
-8.57% | 1.17B |
- Stock Market
- Equities
- AXNX Stock
- News Axonics, Inc.
- Nephron Research Downgrades Axonics to Hold From Buy, Raises Price Target to $71 From $65